All In Biotech

Drug Trial Radar · NCT00940420

A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C

Safety and Tolerability of Ribavirin (Ro 20-9963) in Combination With Peginterferon Alfa in Patients With Chronic Hepatitis C

Last checked: Nov 20, 2026Latest source record: Nov 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,695

Actual

Start

Oct 2002

Primary completion

Nov 2009

Study completion Nov 2009

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 2 arm open-label study will assess the safety and tolerability of combination treatment with Peginterferon alfa (Pegasys) and Ribavirin (Copegus) in patients with chronic hepatitis C. Patients will be assigned to receive Peginterferon alfa (Pegasys) 180 mcg sc once a week and Ribavirin (Copegus) 800 - 1200 mg po daily for either 24 or 48 weeks. Allocation to the treatment arms is to the discretion of the investigator (mainly according to genotype). Adverse events will be monitored throughout the study and hematologic parameters every 2 weeks and twice during the 24-week follow-up.

Conditions

  • Hepatitis C, Chronic

Interventions

  • Copegus (ribavirin)Drug

    800 - 1200 mg po daily for 24 weeks

  • Copegus (ribavirin)Drug

    800 - 1200 mg po daily for 48 weeks

  • peginterferon alfa-2a [Pegasys]Drug

    180 mcg sc once weekly for 24 weeks

  • peginterferon alfa-2a [Pegasys]Drug

    180 mcg sc once weekly for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. safety and tolerability with regard to clinical AEs and laboratory parametersTime frame: assessed every 2 weeks throughout study and after 8 weeks follow-up

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Afula, Israel

  • Site not named

    Ashkelon, Israel

  • Site not named

    Bat Yam, Israel

  • Site not named

    Beersheba, Israel

  • Site not named

    Hadera, Israel

  • Site not named

    Haifa, Israel

  • Site not named

    Haifa, Israel

  • Site not named

    Haifa, Israel

  • Site not named

    Holon, Israel

  • Site not named

    Jerusalem, Israel

  • Site not named

    Kfar Saba, Israel

  • Site not named

    Nahariya, Israel

  • Site not named

    Nazareth, Israel

  • Site not named

    Petah Tikva, Israel

  • Site not named

    Petah Tikva, Israel

  • Site not named

    Ramat Gan, Israel

  • Site not named

    Rehovot, Israel

  • Site not named

    Safed, Israel

  • Site not named

    Tel Aviv, Israel

  • Site not named

    Tsrifin, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.